Watch this interactive, CME-certified video from a live CCO symposium at ASH 2019 where expert faculty review new developments in factor and nonfactor replacement strategies for hemophilia A through case-based examples.
With improved therapies, we can reduce the treatment burden of hemophilia A for patients. Here’s my take on how far we have come and where we are going.
Here’s my take on some of the most exciting hemophilia A studies being presented at the upcoming ASH 2019 meeting in Orlando.
What is the role of pharmacokinetic testing? What is the best option for previously untreated patients? Here’s our take.
Learn the current clinical progress and unmet needs in hemophilia A treatment.
Review of the current and emerging factors including extended half-life factors, immunogenicity, and how to use pharmacokinetics to individualize therapy.
Learn about emicizumab and its impact on monitoring assays and surgical management in hemophilia A.
Learn the rationale and efficacy and safety data for emerging extended half-life factor replacement and nonfactor replacement strategies for hemophilia A, including mimetics, rebalancers, and gene therapy.
Explore practical issues in hemophilia A, including managing breakthrough bleeds, surgery, immune tolerance induction, and previously untreated patients.
Download this quick guide to the latest agents and currently recruiting trials for patients with hemophilia A.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.